Comparison · NCT02035553-sae
Pimavanserin 40 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pimavanserin 40 mg vs Placebo: serious adverse events. Trial comparisons, record NCT02035553-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02035553-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.104 | 0.257 | wilson | |
| Risk in group 2 | 0.11 | 0.0608 | 0.191 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0568 | -0.0456 | 0.16 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.52 | 0.72 | 3.2 | log | |
| Odds ratio, group 1 over group 2 | 1.62 | 0.686 | 3.83 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Pimavanserin 40 mg than on Placebo | 17.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pimavanserin 40 mg | Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin) | 15 | 90 | EG001 |
| Group 2 | Placebo | Placebo, two tablets, once daily by mouth | 10 | 91 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 12 weeks
Source ClinicalTrials.gov
Trial
- Title
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
- NCT number
- NCT02035553
- Phases
- PHASE2
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- Pimavanserin tartrate, Placebo
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Results first posted
- 2017-10-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02035553?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02035553-sae